| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
127,470,000 |
| Market
Cap: |
1.79(B) |
| Last
Volume: |
539,066 |
Avg
Vol: |
1,084,016 |
| 52
Week Range: |
$11.665 - $20.73 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile NeoGenomics operate a network of cancer-focused testing laboratories in the U.S., Europe and Asia. Co.'s testing services include the following: Cytogenetics (karyotype analysis), a study of chromosomes and their relationship to disease; Fluorescence In-Situ Hybridization, a molecular cytogenetic technique that focuses on detecting and localizing the presence or absence of specific DNA sequences and genes on chromosomes; Flow cytometry, a technique utilized to measure the characteristics of cell populations; Immunohistochemistry and Digital Imaging; Molecular testing; and Morphologic analysis, a process of analyzing cells under the microscope.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
8,699 |
11,368 |
11,368 |
11,368 |
| Total Sell Value |
$136,292 |
$185,375 |
$185,375 |
$185,375 |
| Total People Sold |
2 |
2 |
2 |
2 |
| Total Sell Transactions |
2 |
3 |
3 |
3 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Tetrault Lynn A. |
Director |
– • – |
2024-03-04 |
4 |
S |
$15.97 |
$97,579 |
D/D |
(6,112) |
50,062 |
|
12% |
|
| Olivo Alicia C |
General Counsel |
• – – |
2024-02-15 |
4 |
S |
$14.96 |
$38,713 |
D/D |
(2,587) |
34,866 |
|
5% |
|
| Harris Melody |
President, Enterprise Ops |
• – – |
2024-01-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(7,123) |
102,955 |
|
- |
|
| Sherman Jeffrey Scott |
Chief Financial Officer |
• – – |
2023-12-07 |
4 |
D |
$0.00 |
$0 |
D/D |
(8,147) |
125,662 |
|
- |
|
| Stone Warren |
President, Clinical Services |
• – – |
2023-12-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(5,431) |
83,775 |
|
- |
|
| Olivo Alicia C |
General Counsel |
• – – |
2023-11-17 |
4 |
S |
$18.39 |
$49,083 |
D/D |
(2,669) |
37,140 |
|
21% |
|
| Olivo Alicia C |
General Counsel |
• – – |
2023-09-30 |
4 |
D |
$0.00 |
$0 |
D/D |
(14) |
39,498 |
|
- |
|
| Olivo Alicia C |
General Counsel |
• – – |
2023-09-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,666) |
39,411 |
|
- |
|
| Olivo Alicia C |
General Counsel |
• – – |
2023-08-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(14) |
40,981 |
|
- |
|
| Sikri Vishal |
President Advanced Diagnostics |
• – – |
2023-06-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(21,406) |
127,716 |
|
- |
|
| Tetrault Lynn A. |
Director |
– • – |
2023-05-22 |
4 |
OE |
$11.60 |
$17,481 |
D/D |
1,507 |
56,174 |
|
- |
|
| Aunan Greg D |
Chief Accounting OfficerOffice |
• – – |
2023-05-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
15,390 |
|
-36% |
|
| Olivo Alicia C |
General Counsel |
• – – |
2023-05-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(662) |
40,694 |
|
- |
|
| Dieter Cynthia J |
Chief Accounting Officer |
• – – |
2023-03-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(117) |
29,765 |
|
- |
|
| Dieter Cynthia J |
Chief Accounting Officer |
• – – |
2023-03-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(880) |
29,882 |
|
- |
|
| Harris Melody |
President, Enterprise Ops |
• – – |
2023-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
108,225 |
108,225 |
|
- |
|
| Dieter Cynthia J |
Chief Accounting Officer |
• – – |
2022-12-31 |
4 |
D |
$0.00 |
$0 |
D/D |
(959) |
30,762 |
|
- |
|
| Sherman Jeffrey Scott |
Chief Financial Officer |
• – – |
2022-12-05 |
4 |
A |
$0.00 |
$0 |
D/D |
133,809 |
133,809 |
|
- |
|
| Stone Warren |
President, Clinical Services |
• – – |
2022-12-01 |
4 |
A |
$0.00 |
$0 |
D/D |
89,206 |
89,206 |
|
- |
|
| Perez David Brian |
Director |
– • – |
2022-11-03 |
4 |
A |
$0.00 |
$0 |
D/D |
10,300 |
10,300 |
|
- |
|
| Dieter Cynthia J |
Chief Accounting Officer |
• – – |
2022-11-01 |
4 |
A |
$0.00 |
$0 |
D/D |
13,141 |
31,721 |
|
- |
|
| Smith Christopher M |
Chief Executive Officer |
• – – |
2022-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
602,219 |
602,219 |
|
- |
|
| Kulkarni Shashikant |
President of Lab Operations |
• – – |
2022-08-01 |
4 |
A |
$0.00 |
$0 |
D/D |
24,704 |
65,856 |
|
- |
|
| Sholehvar David |
President, Clinical Services |
• – – |
2022-08-01 |
4 |
A |
$0.00 |
$0 |
D/D |
12,352 |
43,216 |
|
- |
|
| Kulkarni Shashikant |
President of Lab OperationsOff |
• – – |
2022-07-07 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
61,728 |
|
- |
|
431 Records found
|
|
Page 1 of 18 |
|
|
0.13 (0.92%) 
